Recently, two double-blind, randomized, placebo-controlled clinical trials suggested that the PDE5 inhibitors have anti-tumor effects on colorectal cancer (CRC) in a national cohort of patients. This evidence concerns the gene PDE5A and colorectal carcinoma.